Avalo Therapeutics, Inc.
AVTX
$4.78
-$0.10-2.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -35.34M | 23.04M | 98.46M | -121.29M | -8.17M |
| Total Depreciation and Amortization | 68.00K | 34.00K | 33.00K | 34.00K | 43.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 0.00 |
| Total Other Non-Cash Items | 20.84M | -33.09M | -113.45M | 116.32M | 5.27M |
| Change in Net Operating Assets | -612.00K | -1.51M | -1.33M | -1.26M | 85.00K |
| Cash from Operations | -15.04M | -11.53M | -16.28M | -6.20M | -2.77M |
| Capital Expenditure | -- | -- | -- | -- | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | 0.00 | 0.00 | 0.00 | 356.00K | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00 | 0.00 | 0.00 | 356.00K | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 69.44M | 0.00 | 0.00 | 115.63M | 1.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.73M | 0.00 | -472.00K | -7.01M | -- |
| Cash from Financing | 67.71M | 0.00 | -472.00K | 108.61M | 1.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.67M | -11.53M | -16.76M | 102.77M | -2.77M |